Overview
- The Medicare GLP‑1 Bridge began July 1 and makes Wegovy (injection and pill), Zepbound KwikPen four‑dose injections, and Foundayo tablets available to qualifying beneficiaries for a $50 monthly copay while the government pays an agreed price of about $250 per month.
- To join, beneficiaries must meet strict BMI and health thresholds, be uninsured for GLP‑1s under Part D for other indications, obtain prior authorization, and have a clinician certify participation in a lifestyle program focused on diet and exercise.
- KFF estimates about 3.8 million Medicare enrollees initially qualify based on 2023 data, drugmakers and industry analysts propose much larger pools, and actual enrollment will determine program cost and reach.
- CMS designed Bridge after pausing the broader BALANCE Part D plan; the demonstration operates outside standard Part D so the $50 copay does not count toward Part D deductibles or annual out‑of‑pocket limits, and rollout faces expected bottlenecks at clinics and pharmacies.
- Analysts project federal costs from the low billions up to roughly $10 billion depending on uptake, and clinicians warn older adults on GLP‑1s need close monitoring for muscle and bone loss and possible drug interactions as the demo collects real‑world safety and outcomes data.